How much dividend does Pharma Mar pay?
Over the past 12 months, Pharma Mar paid a dividend of 0.65 EUR . This corresponds to a dividend yield of about 1.64 %. For the coming 12 months, Pharma Mar is expected to pay a dividend of 0.77 EUR.
Pharma Mar Dividend 2024
Pharma Mar Dividend
0.65 EUR
Pharma Mar Dividend yield
1.64 %
Ticker
PHM.MC
ISIN
ES0169501022
WKN
A2P9YT
How much dividend does Pharma Mar 2024 pay?
According to the latest status from August 2024, Pharma Mar paid a total of 0.65 EUR per share in dividends within the last 12 months. With the current Pharma Mar price of 39.62 EUR, this corresponds to a dividend yield of 1.64 %. A dividend is paid times per year.
| 1.64 % Dividend Yield | = |
|
Historical Pharma Mar Dividends
A dividend is paid times per year. Last year, the payout months were and July.
| Paydate | Dividend |
|---|---|
| 7/12/2024 | 0.65 |
| 7/7/2023 | 0.65 |
| 8/13/2022 | 0.65 |
| 5/28/2021 | 0.6 |
| 7/26/2020 | 0.04 |
| 10/7/2008 | 0.01 |
| 7/7/2007 | 0.01 |
| 8/14/2004 | 0.01 |
| 4/6/2002 | 0.01 |
| 11/7/2001 | 0.02 |
| 9/9/2000 | 0.02 |
| 8/21/1999 | 0.05 |
| 4/3/1999 | 0.01 |
| 7/19/1998 | 125 |
| 7/13/1997 | 50 |
| 10/13/1996 | 100 |
| 2/7/1995 | 100 |
| 7/13/1994 | 100 |
| 8/15/1993 | 100 |
| 2/7/1992 | 100 |
1
2
Pharma Mar dividend history and estimates ES0169501022 · A2P9YT
In 2023, Pharma Mar paid a dividend amounting to 0.65 EUR. Dividend means that Pharma Mar distributes a portion of its profits to its owners.
3 years
5 years
10 years
25 Years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for Pharma Mar provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Pharma Mar’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating Pharma Mar's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Pharma Mar Dividend History
| Date | Pharma Mar Dividend |
|---|---|
| 2028e | 0.77 undefined |
| 2027e | 0.77 undefined |
| 2026e | 0.77 undefined |
| 2025e | 0.77 undefined |
| 2024e | 0.77 undefined |
| 2023 | 0.65 undefined |
| 2022 | 0.65 undefined |
| 2021 | 0.6 undefined |
| 2020 | 0.48 undefined |
| 2008 | 0.06 undefined |
| 2007 | 0.06 undefined |
| 2004 | 0.12 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2004 | 0.12 EUR | 0 EUR |
| 2005 | 0 EUR | 0 EUR |
| 2006 | 0 EUR | 0 EUR |
| 2007 | 0.06 EUR | 0 EUR |
| 2008 | 0.06 EUR | 0 EUR |
| 2009 | 0 EUR | 0 EUR |
| 2010 | 0 EUR | 0 EUR |
| 2011 | 0 EUR | 0 EUR |
| 2012 | 0 EUR | 0 EUR |
| 2013 | 0 EUR | 0 EUR |
| 2014 | 0 EUR | 0 EUR |
| 2015 | 0 EUR | 0 EUR |
| 2016 | 0 EUR | 0 EUR |
| 2017 | 0 EUR | 0 EUR |
| 2018 | 0 EUR | 0 EUR |
| 2019 | 0 EUR | 0 EUR |
| 2020 | 0.48 EUR | 0 EUR |
| 2021 | 0.6 EUR | 0 EUR |
| 2022 | 0.65 EUR | 0 EUR |
| 2023 | 0.65 EUR | 0 EUR |
| 2024e | 0 EUR | 0.77 EUR |
| 2025e | 0 EUR | 0.77 EUR |
| 2026e | 0 EUR | 0.77 EUR |
| 2027e | 0 EUR | 0.77 EUR |
| 2028e | 0 EUR | 0.77 EUR |
Is the Pharma Mar Dividend Safe?
Pharma Mar has been increasing the dividend for 4 years.
Over the past 10 years, Pharma Mar has increased it by an annual 0 %.
Over a five-year period, the distribution increased by 0%.
Analysts expect a Dividend Increase of 8.851% for the current fiscal year.
Pharma Mar dividend payout ratio ES0169501022 · A2P9YT
In 2023, Pharma Mar had a payout ratio of 13.97%. The payout ratio indicates the percentage of the company's profits that Pharma Mar distributes as dividends.
3 years
5 years
10 years
25 Years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for Pharma Mar represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for Pharma Mar could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate Pharma Mar's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Pharma Mar Payout Ratio History
| Date | Pharma Mar Payout ratio |
|---|---|
| 2028e | 17.07 % |
| 2027e | 16.92 % |
| 2026e | 16.18 % |
| 2025e | 18.09 % |
| 2024e | 16.49 % |
| 2023 | 13.97 % |
| 2022 | 23.81 % |
| 2021 | 11.7 % |
| 2020 | 6.41 % |
| 2019 | 13.97 % |
| 2018 | 13.97 % |
| 2017 | 13.97 % |
| 2016 | 13.97 % |
| 2015 | 13.97 % |
| 2014 | 13.97 % |
| 2013 | 13.97 % |
| 2012 | 13.97 % |
| 2011 | 13.97 % |
| 2010 | 13.97 % |
| 2009 | 13.97 % |
| 2008 | -2.69 % |
| 2007 | -2.39 % |
| 2006 | 13.97 % |
| 2005 | 13.97 % |
| 2004 | -9.8 % |
| Payout ratio | |
|---|---|
| 2004 | -9.8 % |
| 2005 | 13.97 % |
| 2006 | 13.97 % |
| 2007 | -2.39 % |
| 2008 | -2.69 % |
| 2009 | 13.97 % |
| 2010 | 13.97 % |
| 2011 | 13.97 % |
| 2012 | 13.97 % |
| 2013 | 13.97 % |
| 2014 | 13.97 % |
| 2015 | 13.97 % |
| 2016 | 13.97 % |
| 2017 | 13.97 % |
| 2018 | 13.97 % |
| 2019 | 13.97 % |
| 2020 | 6.41 % |
| 2021 | 11.7 % |
| 2022 | 23.81 % |
| 2023 | 13.97 % |
| 2024e | 16.49 % |
| 2025e | 18.09 % |
| 2026e | 16.18 % |
| 2027e | 16.92 % |
| 2028e | 17.07 % |
Dividend Details
Understanding Pharma Mar's Dividend Distributions
Pharma Mar’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Year-to-Year Comparison
Examining Pharma Mar's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Impact on Investments
Pharma Mar's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Interpreting Dividend Fluctuations
Changes in Pharma Mar’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
Pharma Mar Aktienanalyse
What does Pharma Mar do?
Pharma Mar SA is a biopharmaceutical company based in Madrid, Spain, focused on developing and marketing innovative cancer treatments. The company originated from Zeltia SA, a business group founded in 1963 that was previously active in various sectors including shipbuilding and fishing. In 1986, Zeltia SA expanded into the pharmaceutical industry and established Pharma Mar SA to concentrate on researching and developing cancer therapies. Over the years, Pharma Mar SA expanded its portfolio through acquisitions and partnerships, such as the acquisition of the biotech company Sylentis in 2006 and a strategic collaboration with Janssen Pharmaceutica in 2014. Today, Pharma Mar SA's business model consists of researching, developing, and marketing cancer treatments based on marine organisms. The company has built an extensive library of marine organisms from which it identifies and develops potential compounds for cancer therapy. Pharma Mar SA is divided into three main business areas: oncology, ophthalmology, and diagnostics. The oncology division focuses on developing and marketing drugs for the treatment of various types of cancer, such as lung cancer, breast cancer, ovarian cancer, and small cell lung cancer. One of Pharma Mar SA's key products in the oncology field is Yondelis, a medication for the treatment of soft tissue sarcomas and ovarian cancer. Yondelis was developed by Pharma Mar SA in collaboration with Janssen Pharmaceutica and is the first medication approved by the European Medicines Agency for the treatment of soft tissue sarcomas. The ophthalmology division focuses on researching and developing drugs for the treatment of eye diseases such as dry eye and retinitis pigmentosa. Pharma Mar SA has a promising pipeline of products in early development, including p118, a compound for the treatment of dry eye that is currently being tested in clinical trials. The diagnostics division focuses on the development of innovative diagnostics for the early detection of cancer and other diseases. Pharma Mar SA has a range of products in development, including a blood test for the detection of lung cancer based on the identification of tumor markers. Overall, Pharma Mar SA has an impressive track record in the development and marketing of cancer treatments from marine organisms. The company has launched several products that contribute to improving the lives of cancer patients and has a promising pipeline of products in development that have the potential to revolutionize the treatment of cancer and other diseases. Pharma Mar is one of the most popular companies on Eulerpool.com.Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Frequently Asked Questions about Pharma Mar stock
What is the dividend yield of Pharma Mar?
The current dividend yield of Pharma Mar is 1.64 %.
When does Pharma Mar pay dividends?
Pharma Mar pays a quarterly dividend. This is distributed in the months of May, August, July, July.
How secure is the dividend of Pharma Mar?
Pharma Mar paid dividends every year for the past 9 years.
What is the dividend of Pharma Mar?
For the upcoming 12 months, dividends amounting to 0.77 EUR are expected. This corresponds to a dividend yield of 1.94 %.
In which sector is Pharma Mar located?
Pharma Mar is assigned to the 'Health' sector.
Wann musste ich die Aktien von Pharma Mar kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Pharma Mar from 6/14/2024 amounting to 0.65 EUR, you needed to have the stock in your portfolio before the ex-date on 6/12/2024.
When did Pharma Mar pay the last dividend?
The last dividend was paid out on 6/14/2024.
What was the dividend of Pharma Mar in the year 2023?
In the year 2023, Pharma Mar distributed 0.65 EUR as dividends.
In which currency does Pharma Mar pay out the dividend?
The dividends of Pharma Mar are distributed in EUR.
Andere Kennzahlen von Pharma Mar
Our stock analysis for Pharma Mar Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharma Mar Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
